In nondiabetic adults with overweight or obesity, the drug Retatrutide lowers levels of LDL cholesterol and triglycerides in the blood by specific amounts, and based on current data, it shows greater...
Mechanism
Synthesis from 1 study
This drug activates three different signals in the body that work together to make the liver burn more fat, make less fat, and remove bad cholesterol faster. This is why it lowers harmful fats in the blood more than other similar drugs.
Most probable mechanism
A drug that activates three different receptors in the body causes fat cells to release stored fat, tells the liver to burn more energy and make less fat, and helps the liver remove bad cholesterol and fats from the blood faster, leading to lower levels of harmful lipids.
Activation of GIP receptors on adipocytes promotes lipolysis and reduces fat storage, increasing free fatty acid flux to the liver.
Activation of glucagon receptors in hepatocytes increases energy expenditure, suppresses de novo lipogenesis, and enhances fatty acid oxidation.
Activation of GLP-1 receptors on hepatocytes and pancreatic beta cells improves insulin sensitivity and reduces glucagon-driven hepatic glucose production, indirectly lowering lipid synthesis.
Combined receptor signaling enhances hepatic uptake and catabolism of atherogenic lipoproteins, including LDL and remnant particles, while reducing the assembly and secretion of very-low-density lipoprotein (VLDL).
Reduced VLDL secretion and increased clearance of circulating lipoproteins lower plasma concentrations of triglycerides and low-density lipoprotein cholesterol.
Less supported by current evidence, but not ruled out
Reducing inflammation in the body lowers the liver's production of fats and cholesterol by calming immune signals that drive lipid synthesis.
GLP-1 receptor activation on monocytes and macrophages inhibits NF-κB signaling, reducing secretion of pro-inflammatory cytokines such as IL-6 and TNF-α.
Lower circulating cytokine levels decrease hepatic stimulation of acute-phase protein synthesis and de novo lipogenesis.
Reduced hepatic lipid synthesis contributes to lower VLDL and LDL production.
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.